IL141603A0 - THE USE OF R(+)-α-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL) ETHYL] -4- PIPERIDINEMETHANOL FOR THE TREATMENT OF SLEEP DISORDERS - Google Patents

THE USE OF R(+)-α-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL) ETHYL] -4- PIPERIDINEMETHANOL FOR THE TREATMENT OF SLEEP DISORDERS

Info

Publication number
IL141603A0
IL141603A0 IL14160399A IL14160399A IL141603A0 IL 141603 A0 IL141603 A0 IL 141603A0 IL 14160399 A IL14160399 A IL 14160399A IL 14160399 A IL14160399 A IL 14160399A IL 141603 A0 IL141603 A0 IL 141603A0
Authority
IL
Israel
Prior art keywords
piperidinemethanol
dimethoxyphenyl
fluorophenyl
treatment
ethyl
Prior art date
Application number
IL14160399A
Other languages
English (en)
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of IL141603A0 publication Critical patent/IL141603A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL14160399A 1998-08-28 1999-07-29 THE USE OF R(+)-α-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL) ETHYL] -4- PIPERIDINEMETHANOL FOR THE TREATMENT OF SLEEP DISORDERS IL141603A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14313598A 1998-08-28 1998-08-28
PCT/US1999/017331 WO2000012090A1 (en) 1998-08-28 1999-07-29 THE USE OF R(+)-α-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL FOR THE TREATMENT OF SLEEP DISORDERS

Publications (1)

Publication Number Publication Date
IL141603A0 true IL141603A0 (en) 2002-03-10

Family

ID=22502745

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14160399A IL141603A0 (en) 1998-08-28 1999-07-29 THE USE OF R(+)-α-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL) ETHYL] -4- PIPERIDINEMETHANOL FOR THE TREATMENT OF SLEEP DISORDERS
IL141603A IL141603A (en) 1998-08-28 2001-02-22 The use of R (+) - α - (3,2– dimethoxyphenyl) -1 - [–2 (4-fluorophenyl) ethyl] - 4 - piperidinemethanol for the preparation of a pharmaceutical preparation for the treatment of sleep disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL141603A IL141603A (en) 1998-08-28 2001-02-22 The use of R (+) - α - (3,2– dimethoxyphenyl) -1 - [–2 (4-fluorophenyl) ethyl] - 4 - piperidinemethanol for the preparation of a pharmaceutical preparation for the treatment of sleep disorders

Country Status (32)

Country Link
EP (2) EP1105132B1 (ko)
JP (1) JP2002523460A (ko)
KR (3) KR100764532B1 (ko)
CN (1) CN1127954C (ko)
AT (1) ATE249830T1 (ko)
AU (1) AU764604B2 (ko)
BG (2) BG109953A (ko)
BR (1) BR9913242A (ko)
CA (2) CA2629396A1 (ko)
CZ (1) CZ300781B6 (ko)
DE (2) DE69911436T2 (ko)
DK (1) DK1105132T3 (ko)
EA (1) EA003791B1 (ko)
EE (1) EE04951B1 (ko)
ES (1) ES2204146T3 (ko)
HK (1) HK1040907B (ko)
HR (2) HRP20010140A2 (ko)
HU (1) HUP0202145A3 (ko)
ID (1) ID29601A (ko)
IL (2) IL141603A0 (ko)
ME (1) MEP20308A (ko)
MX (1) MXPA01002026A (ko)
NO (2) NO20010984L (ko)
NZ (1) NZ510083A (ko)
PL (1) PL195022B1 (ko)
PT (1) PT1105132E (ko)
SK (1) SK284858B6 (ko)
TR (1) TR200100670T2 (ko)
TW (1) TWI233802B (ko)
UA (1) UA74773C2 (ko)
WO (1) WO2000012090A1 (ko)
ZA (1) ZA200101466B (ko)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020099076A1 (en) * 2000-05-25 2002-07-25 Richard Scheyer D. Use of (+)-a-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol or its prodrug in the treatment of symptoms of dementia and dopamine induced psychosis
KR20050025628A (ko) 2002-07-19 2005-03-14 바이오비트럼 에이비 5-ｈｔ2ａ 수용체 관련 장애의 치료를 위한 신규피페라지닐-피라지논 유도체

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5169096A (en) 1985-07-02 1992-12-08 Merrell Dow Pharmaceuticals Inc. N-aralkyl-piperidine-methanol derivatives
US4877798A (en) * 1987-11-23 1989-10-31 Merrell Dow Pharmaceuticals Inc. Treatment of fibromyalgia
ATE102482T1 (de) * 1988-01-21 1994-03-15 Merrell Dow Pharma Verwendung von 1,4-disubstituierten-piperidinyl- verbindungen zur herstellung eines arzneimittels zur behandlung von schlaflosigkeit.
JP2869512B2 (ja) 1990-06-01 1999-03-10 メレルダウファーマスーティカルズ インコーポレイテッド （＋）―α―（２，３―ジメトキシフェニル）―１―［２―（４―フルオロフェニル）エチル］―４―ピペリジンメタノール
JPH05134149A (ja) * 1991-11-08 1993-05-28 Nippondenso Co Ltd 光半導体モジユール
US5618824A (en) * 1994-03-09 1997-04-08 Merrell Pharmaceuticals Inc. Treatment of obsessive-compulsive disorders with 5-HT2 antagonists
EP0796619A1 (en) * 1996-03-21 1997-09-24 Merrell Pharmaceuticals Inc. Use of (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethanol in treating depressive disorders and bipolar disorders
US9702597B1 (en) 2016-02-18 2017-07-11 King Fahd University Of Petroleum And Minerals System and method for preventing absorbent crystallization in a continuously operating solar-powered absorption cooling system with hybrid storage

Also Published As

Publication number Publication date
CZ300781B6 (cs) 2009-08-12
KR100682799B1 (ko) 2007-02-15
TR200100670T2 (tr) 2001-06-21
SK2692001A3 (en) 2001-07-10
NO20010984L (no) 2001-04-25
DE69911436T2 (de) 2004-07-01
HK1040907A1 (en) 2002-06-28
DK1105132T3 (da) 2003-11-24
EE200100122A (et) 2002-06-17
EA200100201A1 (ru) 2001-08-27
JP2002523460A (ja) 2002-07-30
IL141603A (en) 2006-08-20
PT1105132E (pt) 2004-02-27
EP1105132B1 (en) 2003-09-17
BG65416B1 (bg) 2008-07-31
HRP20010140A2 (en) 2002-02-28
KR100764532B1 (ko) 2007-10-09
WO2000012090A1 (en) 2000-03-09
BG109953A (en) 2007-12-28
CZ2001726A3 (en) 2001-06-13
MXPA01002026A (es) 2003-03-27
EA003791B1 (ru) 2003-10-30
EP1105132A1 (en) 2001-06-13
AU764604B2 (en) 2003-08-21
EP1362589B1 (en) 2009-07-15
CA2629396A1 (en) 2000-03-09
BG105289A (en) 2001-11-30
CN1315861A (zh) 2001-10-03
DE69911436D1 (de) 2003-10-23
ATE249830T1 (de) 2003-10-15
EP1362589A1 (en) 2003-11-19
EE04951B1 (et) 2008-02-15
HRP20080389A2 (en) 2008-11-30
HK1040907B (zh) 2004-04-02
HUP0202145A2 (hu) 2003-01-28
ID29601A (id) 2001-09-06
NO20091111L (no) 2001-04-25
NZ510083A (en) 2003-08-29
HUP0202145A3 (en) 2003-02-28
MEP20308A (en) 2010-06-10
ZA200101466B (en) 2002-05-21
KR20060023197A (ko) 2006-03-13
KR20060057029A (ko) 2006-05-25
ES2204146T3 (es) 2004-04-16
TWI233802B (en) 2005-06-11
AU5135999A (en) 2000-03-21
KR20010073026A (ko) 2001-07-31
KR100735513B1 (ko) 2007-07-06
PL195022B1 (pl) 2007-08-31
CA2341891C (en) 2009-05-12
PL346342A1 (en) 2002-02-11
CA2341891A1 (en) 2000-03-09
DE69941134D1 (de) 2009-08-27
UA74773C2 (en) 2006-02-15
CN1127954C (zh) 2003-11-19
NO20010984D0 (no) 2001-02-27
SK284858B6 (sk) 2006-01-05
BR9913242A (pt) 2001-05-15

Similar Documents

Publication Publication Date Title
ZA977783B (en) Method of inhibiting fibrosis with a somatostatin agonist
DK0668763T3 (da) Anvendelse af phenserin til fremstillingen af lægemidler til behandlingen af kognitive sygdomme
DE69800859D1 (de) Verwendung von Moxonidin zur Behandlung neuropathischer Schmerzen
EP1006793A4 (en) COMPOSITIONS FOR TREATING ARRHYTHMIA AND METHODS OF TREATMENT
WO2003015690A3 (en) Method for treating primary insomnia
ZA972345B (en) Use of (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol in treating depressive disorders and bipolar disorders.
AU1656997A (en) Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer
MXPA04000775A (es) Uso novedoso del 2 -[5-(4-fluorofenil) -3-piridilmetilamino-metil] -cromano y sus sales fisiologicamente aceptables.
IL141603A0 (en) THE USE OF R(+)-α-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL) ETHYL] -4- PIPERIDINEMETHANOL FOR THE TREATMENT OF SLEEP DISORDERS
IL126158A0 (en) Method for treating substance abuse
EP0904094A4 (en) TREATMENT OF BONE DISEASES USING ADRENOMEDULLINE
YU15301A (sh) PRIMENA R (+)- alfa-(2,3-DIMETOKSIFENIL)-1-[2-(4-FLUOROFENIL) ETIL] -4-PIPERIDINMETANOLA ZA LECENJE POREMEĆAJA SPAVANJA
MX9704887A (es) Composiciones farmaceuticas para el tratamiento de trastornos depresivos.

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed